NASDAQ:FBIO
Fortress Biotech Stock News
$1.75
-0.0500 (-2.78%)
At Close: May 03, 2024
Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
08:30am, Thursday, 06'th Jan 2022
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or moneti
Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
02:00pm, Tuesday, 21'st Dec 2021 Intrado Digital Media
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will ring the closing bell at the Nasdaq MarketSite in Times Square today, Tuesday, December 21, 2021 at 4:00 p.m. EST. Fortress is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market.
Analysts Anticipate Fortress Biotech, Inc. (NASDAQ:FBIO) Will Announce Quarterly Sales of $29.93 Million
12:22am, Monday, 13'th Dec 2021 Dakota Financial News
Analysts predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will announce $29.93 million in sales for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Fortress Biotechs earnings, with the lowest sales estimate coming in at $15.15 million and the highest estimate coming in at $75.52 million. Fortress Biotech reported sales of []
Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
01:00pm, Friday, 10'th Dec 2021 GlobeNewswire Inc.
Generated record net revenues of $19.6 million for the third quarter of 2021
Fortress Biotech’s (FBIO) Positive Rating Reiterated at UBS Group
10:14am, Friday, 10'th Dec 2021 Dakota Financial News
UBS Group reiterated their positive rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Tuesday, The Fly reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. A number of other research firms also recently weighed in on FBIO. HC Wainwright reaffirmed a buy rating and set a […]
Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference
09:05pm, Tuesday, 07'th Dec 2021 GlobeNewswire Inc.
SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and
Fortress Biotech company initiates rolling submission of CUTX-101 application for Menkes disease
01:38pm, Tuesday, 07'th Dec 2021 Seeking AlphaFortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
01:00pm, Tuesday, 07'th Dec 2021 GlobeNewswire Inc.
NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with suppor
$29.93 Million in Sales Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter
06:40am, Sunday, 05'th Dec 2021 ETF Daily News
Brokerages predict that Fortress Biotech, Inc. (NASDAQ:FBIO) will report sales of $29.93 million for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Fortress Biotechs earnings. The lowest sales estimate is $15.15 million and the highest is $75.52 million. Fortress Biotech posted sales of $13.75 million in the same quarter last [] The post $29.93 Million in Sales Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter appeared first on ETF Daily News .
Fortress Biotech Inc. (NASDAQ:FBIO) Will Likely Reach 24.00 USD!
07:00pm, Saturday, 27'th Nov 2021 Stocks Register
Fortress Biotech Inc. (NASDAQ:FBIO) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.03% to the previous days close as strong demand from buyers drove the stock to $2.83. Actively observing the price movement in the last trading, the stock closed the session at $2.98, falling within a range of $2.805 Fortress Biotech Inc. (NASDAQ:FBIO) Will Likely Reach 24.00 USD! Read More »
Prudential Financial Inc. Boosts Stock Position in Fortress Biotech, Inc. (NASDAQ:FBIO)
11:10am, Friday, 26'th Nov 2021 Transcript Daily
Prudential Financial Inc. grew its stake in shares of Fortress Biotech, Inc. (NASDAQ:FBIO) by 26.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 233,255 shares of the biopharmaceutical companys stock after buying an additional 48,300 shares during the period. Prudential Financial Inc.s holdings in Fortress Biotech were worth $833,000 as of its most recent []
B. Riley Reiterates Buy Rating for Fortress Biotech (NASDAQ:FBIO)
06:12am, Saturday, 20'th Nov 2021 Transcript Daily
B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday, Zacks.com reports. FBIO has been the topic of several other reports. Zacks Investment Research raised Fortress Biotech from a sell rating to a hold rating and set a $3.50 target price on the stock in a []
Fortress Biotechs (FBIO) Buy Rating Reiterated at B. Riley
01:48pm, Friday, 19'th Nov 2021 Dakota Financial News
B. Riley reissued their buy rating on shares of Fortress Biotech (NASDAQ:FBIO) in a research report released on Wednesday morning, Zacks.com reports. FBIO has been the subject of several other research reports. Zacks Investment Research raised shares of Fortress Biotech from a sell rating to a hold rating and set a $3.50 price target for []
-$0.09 EPS Expected for Fortress Biotech, Inc. (NASDAQ:FBIO) This Quarter
04:28pm, Wednesday, 17'th Nov 2021 Dakota Financial News
Wall Street analysts forecast that Fortress Biotech, Inc. (NASDAQ:FBIO) will post earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Fortress Biotechs earnings, with the highest EPS estimate coming in at $0.09 and the lowest estimate coming in at ($0.15). Fortress Biotech posted []
Fortress Biotech (NASDAQ:FBIO) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS
03:44pm, Wednesday, 17'th Nov 2021 Dakota Financial News
Fortress Biotech (NASDAQ:FBIO) issued its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06), Fidelity Earnings reports. Fortress Biotech had a negative net margin of 63.05% and a negative return on equity of 15.34%. Shares of NASDAQ FBIO traded up $0.01 on []